A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
In 2008, InnoMed PredTox, a collaboration with pharmaceutical companies, research organizations, and the European Commission to improve the safety of drugs, which included Lilly S.A. in Switzerland, secured an €8 million budget for a 40-month project that was coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), an organization who represents the research-based pharmaceutical industry and biotech companies operating in Europe. In 2008, Lilly's activities included research projects within the framework of the Innovative Medicines Initiative, a public-private research initiative in Europe that is a joint effort of the EFPIA and the European Commission. In January 2009, the largest criminal fine in US history, totaling $1.415 billion, was imposed on Lilly for illegal marketing of its best-selling product, the atypical antipsychotic medication, Zyprexa. In January 2011, Boehringer Ingelheim and Lilly announced a global agreement to jointly develop and market new APIs for diabetes therapy. Lilly could receive more than $1 billion for their work on the project, while Boehringer Ingelheim could receive more than $800 million from development of the new drugs. Boehringer Ingelheim's oral anti-diabetic Linagliptin, BI 1077, and two of Lilly's insulin analogs, LY2605541 and LY2963016, were in phase II and III of clinical development at that time. In April 2014, Lilly acquired Switzerland-based Novartis AG's animal health business for $5.4 billion in cash to strengthen and diversify its Elanco unit.
Breadfruit – used similarly as jackfruit in savory dishes Coconut burger – made from sapal, the coconut pulp by-products of traditional coconut milk extraction in Filipino cuisine Eggplant – semitropical/tropical plant with a highly textured flesh Grapefruit – during the course of the Special Period economic crisis Cubans prepared steaks made out of breaded and fried grapefruit rind known as "bistec de toronja". Jackfruit – a fruit whose flesh has a similar texture to pulled pork when cooked
Vincent Marks (10 June 1930 – 6 November 2023) was an English pathologist and clinical biochemist known for his works on studying insulin and hypoglycemia. His contributions to medical science include simplifying low blood glucose testing, introducing insulin radioimmunoassay, and advancing diabetes research. Marks played an important role in high-profile medico-legal cases, notably providing expert testimony that helped acquit Danish-born British socialite Claus von Bülow in 1985, a case that was the basis of the Oscar-winning movie Reversal of Fortune (1990). Marks was also a nutritionist who studied intestinal hormones and coined the term "muesli belt malnutrition", referring to parents feeding their children what is considered extremely healthy foods, but, in the process depriving them of essential fats.
Sources: en.wikipedia.org
=== Staudinger ligation === The Staudinger ligation, first reported in 2000, in principle enables the ligation of peptide segments independent of the terminal amino acids. The method is based on the Staudinger reaction. The Staudinger ligation continues to be developed but has not yet found widespread use.
=== Media presence === Collins has been a subject of press and tabloid attention since she first began appearing on The Only Way Is Essex in 2011. Her battle with her weight is something that has been widely documented throughout her career, however she has been consistently praised for her confidence, and has promoted body positivity and encouraged women to love themselves no matter what their size. Collins has a large following on social media, having amassed over 2 million followers on Instagram and over 1 million on Twitter. Such is her popularity, she is often paid to promote products and businesses on her pages and can earn up to £75,000 in one day from social media posts. Collins has stated that she only endorses products that she believes in. Collins is widely known for her diva meltdowns and recognisable catchphrases during her appearances on television and in the media, and as a result became the subject of numerous internet memes. She was branded the "meme queen" by the BBC whilst Peter Robinson of The Guardian described her as a "social media powerhouse who has literally made a meme out of mispronouncing the word meme". Collins is a staple of the "hun subculture" and has been regarded as the "Queen of Huns". Her popularity within the LGBT community has seen her make various appearances at nightclubs and events including G-A-Y and Glitterbomb. In June 2023, she performed at the Mighty Hoopla event in Brockwell Park.
Prolonged mineralization lag time (greater than 100 days) Widened osteoid seams (increased osteoid thickness) Increased osteoid volume Vitamin D metabolism disorders: Rickets and osteomalacia develop in various clinical situations and have in common an absence or delay in the mineralization of growth cartilage and newly formed bone collagen. Deficiency of vitamin D, essential for absorption of dietary calcium, has been a major cause historically.
== Function == The main purpose of chondronectin is to allow chondrocytes and collagen II substrates to bond together. When bound, if forms a complex structure called an extracellular scaffold, which helps support the surrounding cells because of bioactive molecule diversity, which allows for chondrocytes to be anchored, mechanical forces to be bared, and maintaining physiological homeostasis. In order for chondronectin to be able to assist in binding within this complex as efficiently as possible, they must interact with a cartilage proteoglycan monomer. If there is a inhibitor that prevents synthesis of endogenous proteoglycans, along with beta-xylosides, it fully prevents chondrocytes from attaching via chondronectins. When cartilage cells attach chondronectin help keep the cells positioned close to important collagen and proteoglycan materials within the extracellular matrix. This allows the cells to support the framework by maintaining surrounding cartilage components. Without attachment, chondrocytes become less effective at preserving the tissue around them. Chondronectin keeps the cartilage framework strong enough to handle daily joint pressure. It helps cartilage deal with the stress caused by regular movement and compression. Since joints face constant wear, cell bonds must stay stable to help prevent tissue damage. This protein plays a key role in keeping cartilage durable and properly supported. Studies indicate that weak adhesive interaction inside cartilage matrix can gradually reduce the integrity to cartilage.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.